keyword
MENU ▼
Read by QxMD icon Read
search

SREs in metastatic prostate cancer

keyword
https://www.readbyqxmd.com/read/29724482/physician-visits-and-the-timing-of-skeletal-related-events-among-men-newly-diagnosed-with-metastatic-prostate-cancer-a-cohort-analysis
#1
Eberechukwu Onukwugha, Husam Albarmawi, Kai Sun, C Daniel Mullins, Abdalla Aly, Arif Hussain
INTRODUCTION: Men diagnosed with metastatic prostate cancer (PCa) are at increased risk for skeletal complications which are associated with significant morbidity and mortality. Although both the urologist and the medical oncologist play important roles in the management of patients with advanced PCa, there is limited information regarding their role in the context of skeletal complications. The current study investigated these relationships among newly diagnosed metastatic patients with PCa...
April 30, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29577024/healthcare-resource-utilization-associated-with-radiation-to-bone-across-eight-european-countries-results-from-a-retrospective-study
#2
Roger von Moos, Jean-Jacques Body, Oliver Guenther, Evangelos Terpos, Yves Pascal Acklin, Jindrich Finek, João Pereira, Nikos Maniadakis, Guy Hechmati, Susan Talbot, Harm Sleeboom
Background: Bone metastases and lytic lesions due to multiple myeloma are common in advanced cancer and can lead to debilitating complications (skeletal-related events [SREs]), including requirement for radiation to bone. Despite the high frequency of radiation to bone in patients with metastatic bone disease, our knowledge of associated healthcare resource utilization (HRU) is limited. Methods: This retrospective study estimated HRU following radiation to bone in Austria, the Czech Republic, Finland, Greece, Poland, Portugal, Sweden and Switzerland...
March 2018: Journal of Bone Oncology
https://www.readbyqxmd.com/read/29373875/the-economic-burden-of-metastatic-castration-resistant-prostate-cancer-and-skeletal-related-events-in-japanese-university-hospitals
#3
Takefumi Satoh, Dianne Ledesma, Nariaki Yoshihara
Objective: Although androgen deprivation therapy (ADT) has improved the survival and quality of life of patients with prostate cancer, resistance to treatment inevitably results in transition to a castration resistant state (CRPC) and, in advanced cases, bone metastasis, leading to skeletal related events (SRE). In order to understand the current burden on patients in Japan, there is a need to estimate the healthcare costs of CRPC treatment in current clinical practice. Methods: This retrospective observational cohort study utilized claims data from 13 national university hospitals through the Platform for Clinical Information Statistical Analysis database...
January 27, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29278410/bisphosphonates-for-advanced-prostate-cancer
#4
REVIEW
Sascha Macherey, Ina Monsef, Franziska Jahn, Karin Jordan, Kwok Keung Yuen, Axel Heidenreich, Nicole Skoetz
BACKGROUND: The prevalence and incidence of pain and skeletal complications of metastatic bone disease such as pathologic fractures, spinal cord compression and hypercalcemia is high and an important contributor to morbidity, poor performance status and decreased quality of life. Moreover, pathologic fractures are associated with increased risk of death in people with disseminated malignancies. Therefore, prevention of pain and fractures are important goals in men with prostate cancer at risk for skeletal complications...
December 26, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29091013/cost-of-illness-of-metastatic-prostate-cancer-a-perspective-of-costs-for-new-treatment-options-in-the-netherlands
#5
Rob Ter Heine, Geert Wj Frederix, Joost W Geenen, Anke M Hövels, Marco van Vulpen, Anko Kooistra, John Mh De Klerk, Haiko J Bloemendal
AIM: To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs). METHODS: We performed a bottom-up cost of illness study in The Netherlands. RESULTS: A total of 136 patients were studied. The mean total costs were €17,931 per patient. SREs that required hospitalization (n = 53) were, at median costs of €2039-9346, depending on care. These SREs had median costs of €200-1912...
October 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28856087/complications-of-bone-metastases-from-malignant-melanoma
#6
Jamal Zekri, Maria Marples, Dominic Taylor, Kiran Kandukurti, Lucy McParland, Janet E Brown
INTRODUCTION: Metastatic bone disease (MBD) carries significant morbidity for patients with cancer. MBD from malignant melanoma (MM) is understudied. We examined the characteristics, morbidity, management and outcome of MBD in patients with MM. METHODS: Patients with metastatic MM managed at two referral cancer centres in England were identified. Those with bone metastases (BMs) were selected. Patient and disease characteristics including skeletal related events (SREs) were extracted from medical records...
September 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/28644302/the-role-of-bone-targeted-therapies-for-prostate-cancer-in-2017
#7
Samer L Traboulsi, Fred Saad
PURPOSE OF REVIEW: Bone-targeted agents (BTAs), such as zoledronic acid and denosumab, delay the occurrence of skeletal-related events (SREs) in metastatic prostate cancer (PCa) patients. Recently, several agents, such as abiraterone acetate, enzalutamide and radium-223, were approved for the treatment of metastatic castration-resistant PCa (mCRPC). These agents resulted in improved overall survival (OS), pain control and had positive effects on bone health. Combining BTAs to the newly approved agents demonstrates additional benefits that warrant a review of available evidence looking at appropriate combination therapies and timing of BTAs for optimizing the management of advanced and metastatic PCa...
September 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28449621/emerging-role-of-radium-223-in-the-growing-therapeutic-armamentarium-of-metastatic-castration-resistant-prostate-cancer
#8
REVIEW
Maria Picciotto, Tindara Franchina, Alessandro Russo, Giuseppina Rosaria Rita Ricciardi, Giusy Provazza, Serena Sava, Sergio Baldari, Orazio Caffo, Vincenzo Adamo
During the last few years, the therapeutic armamentarium of castration resistant prostate cancer (mCRPC) has been enriched with the introduction of new effective therapies with proved survival benefit and quality of life gain, including cabazitaxel, abiraterone, enzalutamide, and Radium-223. Areas covered: Bone metastases represent a substantial cause of morbidity in mCRPC with a high rate of related skeletal events (SREs). In case of multifocal pain due to diffuse osteoblastic metastases, treatment with bone-targeting radiopharmaceutical agents can provide palliation from pain...
June 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28392837/denosumab-treatment-in-the-management-of-patients-with-advanced-prostate-cancer-clinical-evidence-and-experience
#9
REVIEW
Miriam Hegemann, Jens Bedke, Arnulf Stenzl, Tilman Todenhöfer
Osteoprotective therapies have become an essential component in the management of advanced prostate cancer (PC) patients as bone metastases (BMs) have a major impact on morbidity and mortality. Denosumab is a fully humanized antibody targeting the receptor activator of nuclear factor κB ligand (RANKL), which has been approved by the European Medicines Agency (EMA) in Europe and the United States (US) Food and Drug Administration (FDA) in the US for prevention of skeletal-related events (SREs) in patients with solid tumors and BMs, including PC...
March 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28045115/skeletal-related-events-significantly-impact-health-related-quality-of-life-in-metastatic-castration-resistant-prostate-cancer-data-from-prevail-and-affirm-trials
#10
F Saad, C Ivanescu, D Phung, Y Loriot, S Abhyankar, T M Beer, B Tombal, S Holmstrom
BACKGROUND: We investigated the impact of skeletal-related events (SREs) on health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) in phase III trials of enzalutamide versus placebo. METHODS: Patients with mCRPC experiencing at least one SRE during AFFIRM and PREVAIL were assessed for trajectory-adjusted mean change in HRQoL by first SRE using Functional Assessment of Cancer Therapy-Prostate (FACT-P; AFFIRM, three domains, and PREVAIL, nine domains) and EQ-5D (PREVAIL) instruments...
March 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28026865/factors-predicting-skeletal-related-events-in-patients-with-bone-metastatic-castration-resistant-prostate-cancer
#11
Zachary Klaassen, Lauren E Howard, Amanda de Hoedt, Christopher L Amling, William J Aronson, Matthew R Cooperberg, Christopher J Kane, Martha K Terris, Stephen J Freedland
BACKGROUND: Skeletal-related events (SREs) are common complications of bone metastatic castration-resistant prostate cancer (mCRPC). To the authors' knowledge, there are limited data regarding which factors predict SREs. The authors identified risk factors for SREs in men with bone mCRPC using characteristics commonly available in the medical record. METHODS: Data from 454 patients with nonmetastatic CRPC were identified from 2 Veteran Affairs Medical Centers from 2000 through 2013...
May 1, 2017: Cancer
https://www.readbyqxmd.com/read/27730756/risk-of-skeletal-related-events-among-elderly-prostate-cancer-patients-by-site-of-metastasis-at-diagnosis
#12
Arif Hussain, Abdalla Aly, C Daniel Mullins, Yi Qian, Jorge Arellano, Eberechukwu Onukwugha
The purpose of this study was to estimate the risk of developing skeletal-related events (SREs) based on site of metastasis at diagnosis and identify other predictors of developing SREs among metastatic prostate cancer patients. We conducted a retrospective cohort study using linked SEER (Surveillance, Epidemiology, and End Results) and Medicare data and identified men over the age of 65 with incident metastatic prostate cancer diagnosed during 2005-2009. SREs included radiation (RAD), pathological fractures (PF), bone surgery (BS), and spinal cord compression (SCC)...
November 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27478111/opioid-use-among-metastatic-prostate-cancer-patients-with-skeletal-related-events
#13
Avin Yaldo, Lonnie Wen, Augustina Ogbonnaya, Adriana Valderrama, Jonathan Kish, Michael Eaddy, Charles Kreilick, Krishna Tangirala, Katarzyna Shields
PURPOSE: The development of skeletal-related events (SREs) (pathologic fracture, need for surgery and/or radiation to bone, spinal cord compression, and hypercalcemia of malignancy) in metastatic prostate cancer (MPC) is associated with worsened pain and compromised quality of life. Opioids are frequently used throughout the course of SRE treatment. This study describes the treatment patterns and incremental use of opioids in MPC patients diagnosed with SREs. METHODS: PC patients with bone metastases newly diagnosed with an SRE between January 1, 2005, and September 30, 2014, were identified using MarketScan Commercial and Medicare databases...
August 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27434595/trapeze-a-randomised-controlled-trial-of-the-clinical-effectiveness-and-cost-effectiveness-of-chemotherapy-with-zoledronic-acid-strontium-89-or-both-in-men-with-bony-metastatic-castration-refractory-prostate-cancer
#14
RANDOMIZED CONTROLLED TRIAL
Nicholas James, Sarah Pirrie, Ann Pope, Darren Barton, Lazaros Andronis, Ilias Goranitis, Stuart Collins, Duncan McLaren, Joe O'Sullivan, Chris Parker, Emilio Porfiri, John Staffurth, Andrew Stanley, James Wylie, Sharon Beesley, Alison Birtle, Janet Brown, Prabir Chakraborti, Martin Russell, Lucinda Billingham
BACKGROUND: Bony metastatic castration-refractory prostate cancer is associated with a poor prognosis and high morbidity. TRAPEZE was a two-by-two factorial randomised controlled trial of zoledronic acid (ZA) and strontium-89 (Sr-89), each combined with docetaxel. All have palliative benefits, are used to control bone symptoms and are used with docetaxel to prolong survival. ZA, approved on the basis of reducing skeletal-related events (SREs), is commonly combined with docetaxel in practice, although evidence of efficacy and cost-effectiveness is lacking...
July 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27377207/do-skeletal-related-events-predict-overall-survival-in-men-with-metastatic-castration-resistant-prostate-cancer
#15
L E Howard, A M De Hoedt, W J Aronson, C J Kane, C L Amling, M R Cooperberg, M K Terris, C H Divers, A Valderrama, S J Freedland
BACKGROUND: Skeletal-related events (SREs) including pathologic fracture, spinal cord compression, radiation to bone and surgery to bone, are common in men with bone metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC are at high risk of death. Whether SREs predict mortality is unclear. We tested the association between SREs and overall survival (OS) in a multiethnic cohort with bone mCRPC, controlling for key covariates unavailable in claims data such as bone pain, number of bone metastases and PSA doubling time (PSADT)...
December 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27112196/a-multicenter-retrospective-epidemiologic-survey-of-the-clinical-features-and-management-of-bone-metastatic-disease-in-china
#16
MULTICENTER STUDY
Yunpeng Yang, Yuxiang Ma, Jin Sheng, Yan Huang, Yuanyuan Zhao, Wenfeng Fang, Shaodong Hong, Ying Tian, Cong Xue, Li Zhang
BACKGROUND: Bone metastases are common in patients with advanced cancer. Bisphosphonates (BPs) could prevent or delay the development of skeleton-related events (SREs). The present study aimed to identify the clinical features of and treatment strategies for Chinese patients with bone metastases. METHODS: Consecutive cancer patients who had bone metastases and received BP treatment were enrolled. A questionnaire was developed to collect the patients' clinical data, as well as information on the diagnosis and management of bone metastases...
April 25, 2016: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/27042152/targeting-bone-metastases-in-metastatic-castration-resistant-prostate-cancer
#17
REVIEW
Joelle El-Amm, Jeanny B Aragon-Ching
Skeletal involvement in metastatic castrate-resistant prostate cancer (mCRPC) is common and results in significant morbidity and mortality. The interaction of prostate cancer with the bone microenvironment contributes to progression of cancer in the bone leading to skeletal-related events (SREs). Studies aimed at targeting the bone have been carried out over the recent years. Bisphosphonates are synthetic pyrophosphate analogs first investigated for their role in SRE prevention with zoledronic acid as the main bisphosphonate that is approved by the US Food and Drug Administration for retardation of skeletal events in men with metastatic prostate cancer...
2016: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/26865591/the-clinical-and-economic-impacts-of-skeletal-related-events-among-medicare-enrollees-with-prostate-cancer-metastatic-to-bone
#18
Jean A McDougall, Aasthaa Bansal, Bernardo H L Goulart, Jeannine S McCune, Andy Karnopp, Catherine Fedorenko, Stuart Greenlee, Adriana Valderrama, Sean D Sullivan, Scott D Ramsey
BACKGROUND: Approximately 40% of men diagnosed with metastatic prostate cancer experience one or more skeletal-related events (SREs), defined as a pathological fracture, spinal cord compression, or surgery or radiotherapy to the bone. Accurate assessment of their effect on survival, health care resource utilization (HCRU), and cost may elucidate the value of interventions to prevent SREs. MATERIALS AND METHODS: Men older than age 65 years with prostate cancer and bone metastasis diagnosed between 2004 and 2009 were identified from linked Surveillance Epidemiology and End Results-Medicare records...
March 2016: Oncologist
https://www.readbyqxmd.com/read/26860123/high-serum-alp-level-is-associated-with-increased-risk-of-denosumab-related-hypocalcemia-in-patients-with-bone-metastases-from-solid-tumors
#19
Yuka Kinoshita, Makoto Arai, Nobuaki Ito, Yuichi Takashi, Noriko Makita, Masaomi Nangaku, Yusuke Shinoda, Seiji Fukumoto
Metastatic bone disease is one of the most common complications of advanced cancers. Pathological fractures, spinal cord compression, and radiotherapy or surgery to the bone are collectively called skeletal-related events (SREs), which cause severe pain, increase hospitalization rates, and impair the quality of life (QOL) of patients with bone metastases. The receptor activator of nuclear factor-kB ligand (RANKL)/RANK pathway is critical in the progression of bone metastases. Previous studies have demonstrated that an anti-RANKL antibody (denosumab) was superior to zoledronic acid in prolonging time to first SRE in patients with bone metastases from prostate and breast cancers...
May 31, 2016: Endocrine Journal
https://www.readbyqxmd.com/read/26794729/clinical-outcomes-and-survival-following-treatment-of-metastatic-castrate-refractory-prostate-cancer-with-docetaxel-alone-or-with-strontium-89-zoledronic-acid-or-both-the-trapeze-randomized-clinical-trial
#20
RANDOMIZED CONTROLLED TRIAL
Nicholas D James, Sarah J Pirrie, Ann M Pope, Darren Barton, Lazaros Andronis, Ilias Goranitis, Stuart Collins, Adam Daunton, Duncan McLaren, Joe O'Sullivan, Christopher Parker, Emilio Porfiri, John Staffurth, Andrew Stanley, James Wylie, Sharon Beesley, Alison Birtle, Janet Brown, Prabir Chakraborti, Syed Hussain, Martin Russell, Lucinda J Billingham
IMPORTANCE: Bony metastatic castrate-refractory prostate cancer (CRPC) has a poor prognosis and high morbidity. Zoledronic acid (ZA) is commonly combined with docetaxel in practice but lacks evidence that combining is effective, and strontium-89 (Sr89) is generally used palliatively in patients unfit for chemotherapy. Phase 2 analysis of the TRAPEZE trial confirmed combining the agents was safe and feasible, and the objectives of phase 3 include assessment of the treatments on survival...
April 2016: JAMA Oncology
keyword
keyword
71302
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"